Kingston General Hospital
Kingston, Ontario, K7L 2V7, Canada
NCT Number: NCT01385800
Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass pollen. ToleroMune Grass is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of grass allergy.
This study will look at the efficacy, safety and tolerability of three doses of ToleroMune Grass in grass allergic subjects following challenge with with grass in an Environmental Exposure Unit (EEU).
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Kingston, Ontario, K7L 2V7, Canada
This study is designed as a randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability of ToleroMune Grass in grass allergic subjects with allergic rhinoconjunctivitis. The efficacy of ToleroMune Grass will be explored in subjects using an EEU (Environmental Exposure Unit).
The study will consist of 3 study periods. In Period 1, Screening will be performed up to a maximum of 16 weeks before randomisation and may consist of one or two visits to the clinic, at the Investigator's discretion. Baseline Challenge will consist of 4 visits to the EEU at least 3 days before randomisation.
In Period 2, subjects in each cohort complying with the inclusion/exclusion criteria will be randomised to one of four groups and will receive treatment every 2 weeks (±2 days) for 14 weeks.
In Period 3, Post Treatment Challenge will consist of 4 visits to the EEU about 25 weeks after the first administration in the treatment period and assessments will be performed identical to those at the baseline challenge. Follow-up will be conducted 3-10 days after PTC.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intradermal injection 1 x 8 administrations 2 weeks apart
Intradermal injection 1 x 8 administrations 2 weeks apart
Time frame: Upto 25 weeks
Time frame: Upto 25 weeks
Time frame: Upto 25 weeks
Time frame: Up to 25 weeks
Time frame: Upto 26 weeks
Time frame: Upto 26 weeks
Time frame: Up to 26 weeks
Time frame: Up tp 26 weeks
Circassia Limited
Industry
A Double-blind, Randomised, Placebo-controlled Study to Evaluate Three Doses of ToleroMune Grass in Grass Allergic Subjects Following Challenge With Grass Allergen in an Environmental Exposure Unit
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02075138
Grass Allergy, Rhinoconjunctivitis
Washington D.C., District of Columbia, United States
View Trial DetailsNCT02292875
Grass Allergy, Rhinoconjunctivitis
Kanata, Ontario, Canada
View Trial DetailsNCT01923779
Grass Allergy, Rhinoconjunctivitis
View Trial DetailsNCT01728285
Allergic Rhinitis, Behavior
Pavia, PV, Italy
View Trial Details